

28 April 2022

EGM Presentation

Executive Chairman Professor Bernard Tuch

ASX: LCT | OTCQB: LVCLY



Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Corporate Snapshot

Share Price

A\$0.008

As at 20 April 2022

Market Capitalisation

A\$8.2m

Shares on Issue

1,028m

Options


459m

Cash

A\$3.7m

As at 28 February 2022

Share Distribution



■ Top 40 Shareholders ■ Others

Experienced Leadership



**Professor
Bernie Tuch**

Chair,
Interim CEO



**Robert
Willcocks**

Non-Executive
Director



**Professor
Carolyn Sue
AM**

Non-Executive
Director



**Dr Andrew
Kelly**

Non-Executive
Director



**Mark
Licciardo**

Company
Secretary



A Growing Global Market

**Parkinson's
disease market
to reach
US\$11.5bn
by 2029**

- Worth US\$5.7B by 2022 and US\$11.5B by 2029
- CAGR of 12.6% driven by an ageing population
- 10M people with Parkinson's disease globally; 100,000 in Australia alone



Untapped Market

- The only treatments for management of Parkinson's Disease are drugs or medical implants to modulate the symptoms and signs of the disease
- There is currently no treatment to prevent progression of Parkinson's



NTCELL Project

Source of Pigs


Sub-Antarctic Auckland
Islands Pigs
*Designated Pathogen-
free*



Choroid plexus

Surgical removal of brain
tissue choroid plexus
Transported to Sydney


Encapsulation of cell clusters



Regulatory approval from TGA

Clinical Trial

50+ Parkinson's
disease patients



Successful outcome

Commercialisation




Establishing Pig Source

- Tissue source from designated pathogen-free (DPF) Auckland Islands pigs bred and maintained in NZeno facilities, Invercargill secured
- Service Agreement signed with NZeno Jan 2022
- Pig facility being built to house pig herd
- Surgical facility being built to remove choroid plexus under aseptic conditions
- Choroid plexus to be flown to laboratory in Sydney, with 1st delivery expected 1st week in May



Manufacturing

- Perfecting our manufacturing process
- NTCELL to be prepared in non-GMP facility in readiness to move to a GMP facility elsewhere in NSW
- Research Agreement signed with University of Technology Sydney in March to allow for production of NTCELL in non-GMP facility
- Exploring use of AI in maintaining and selecting optimal NTCELL





Regulatory Approval

- Regulatory approval required from Human Research Ethics Committee and Therapeutic Goods Administration (TGA)
- Likely to be the first Australian xenotransplantation trial with living cells
- Approval for two similar trials was obtained from Medsafe, the NZ equivalent of the TGA, in 2012 and 2015




Australian Government

Department of Health
Therapeutic Goods Administration

Clinical Trial and Monitoring


- Aim is to modulate disease progression. Our phase I/II trials demonstrated safety and identified effective dosages
- Planned site of clinical trial is Sydney, where a state-of-the-art PET scanner is being installed. This scanner can detect changes at a level of sophistication not previously available
- Professor Carolyn Sue (LCT Non-Executive Director) is an international authority on Parkinson's disease
- Patients recruited to the trial early to mid-stage Parkinson's disease
- Plan to recruit 50+ recipients; half will receive NTCELL via surgical implantation





NTCELL Timeline

PROPOSED PROJECT TIMELINE



Other Research and Development Initiatives

- Diabecell a potential future revenue stream via Otsuka Pharmaceutical Factory, which is seeking FDA approval for the product. LCT has 5% royalty on eventual product sales that use Immupel encapsulation technology
- Other value-adding opportunities under active consideration



Investor Milestones

NTCELL: Confirmation of manufacture in non-GMP facility	Q3 2022
GMP manufacturing commences	Q4 2022
Regulatory approval for third clinical trial	Q4 2023
First implants in human trial participants	Q1 2024
Other value-adding opportunities	To be confirmed

Note: Timing expectations are based on current best estimates and may be subject to change



@lctglobal



LCT - Living Cell Technologies



@lctglobal

lctglobal.com